Cart is empty The United States said Wednesday it had approved GSK’s Arexy vaccine against Respiratory Syncytial Virus (RSV), which can cause severe symptoms in infants and the elderly, for people aged 60 and older.
The United States said Wednesday it had approved GSK’s Arexy vaccine against Respiratory Syncytial Virus (RSV), which can cause severe symptoms in infants and the elderly, for people aged 60 and older.
Leave A Comment